George Van Antwerp, VP, Product Development, InVentiv Medical Management, suggests the pharmacy benefit manager (PBM) industry is truly exploring new ways of interacting with payers and providers.
George Van Antwerp, VP, Product Development, InVentiv Medical Management, suggests the pharmacy benefit manager (PBM) industry is exploring new ways of interacting with payers and providers. Companies like Prime Therapeutics are making value-based contracting deals that will require looking at data integration.
Mr Antwerp says such innovation will help PBMs better understand how to engage consumers in focusing on care and health management.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More